Picture courtesy Twitter
Pune: Serum Institute of India (SII) has applied to the Drugs Controller General of India (DCGI) and Union Health ministry for full market authorization of its COVID-19 vaccine Covishield.
Adar Poonawalla, the CEO of SII, tweeted on Friday that the Indian government now has enough data to consider a full market authorization of Oxford-AstraZeneca’s COVID which is produced under the brand name Covishield by the Pune-based firm.
Once the drug regulator and government give the go-ahead, Covishield will be available in medical stores.
Since being approved by DGCI for emergency use in January 2021, Covishield along with Bharat Biotech’s indigenously manufactured Covaxin has been used in India’s massive inoculation programme.
SII, the world’s biggest vaccine maker, has till date supplied over 1.25 billion doses of Covishield, which most Indians have received.
SII currently makes 240 million doses per month and is ready to export ‘large volumes’ from January, Poonawalla told Reuters.
Berhampur: A stone weighing 2 kg fell from the ‘Singhadwara Gumuta’ of the Lord Jagannath…
New Delhi: Recent pictures of Space Station Commander Sunita Williams from the International Space Station…
Mumbai: Actress Rupali Ganguly recently filed a Rs 50 crore defamation case against her stepdaughter…
Chennai: Odisha will face Manipur in the semifinals of the 14th Hockey India Senior Men’s…
New Delhi: India will again ask Canada for the extradition of designated Khalistani terrorist Arshdeep Singh…
Berhampur: Police have arrested a man from West Bengal for allegedly claiming himself to be…
Mumbai: Carving a niche for himself in Bollywood was not a cakewalk for ‘The Family…
Mumbai: Mukesh Khanna’s Indian superhero series ‘Shaktimaan’ has been making headlines for quite some time…